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Background:  Inﬂuenza  vaccine  is moderately  effective  for preventing  inﬂuenza  illness.  It is not  known  if
vaccination  reduces  the  risk of  subsequent  hospital  admission  among  patients  with  vaccine  failure  and
laboratory  conﬁrmed  inﬂuenza  illness.
Methods:  Patients  in a community  cohort  presenting  with  acute  respiratory  illness were  prospectively
enrolled  and  tested  for  inﬂuenza  during  8  seasons  to  estimate  seasonal  vaccine  effectiveness.  Hospital
admissions  within  14  days  after  illness  onset  were  identiﬁed  for all participants  aged ≥20  years  with
laboratory  conﬁrmed  inﬂuenza.  The  association  between  vaccination  and  hospital  admission  was  exam-
ined  in  a propensity  score  adjusted  logistic  regression  model.  The  model  was  validated  by examining  the
association  between  vaccination  and  hospital  admission  in  participants  without  inﬂuenza.
Results:  Inﬂuenza  was  identiﬁed  in  1393  (28%)  of 4996  participants.  Sixty-two  (6%)  of 1020  with  inﬂuenza
A  and  17  (5%)  of  369  with  inﬂuenza  B were  hospitalized.  Vaccination  was  not  associated  with  a  reduced
risk  of hospital  admission  among  all  participants  with  inﬂuenza  [adjusted  odds  ratio  (aOR)  =  1.08;  95%  CI:
0.62, 1.88];  or among  those  with  inﬂuenza  A (aOR  =  1.35;  95%  CI: 0.71,  2.57)  or inﬂuenza  B (aOR =  0.67;
95%  CI:  0.21,  2.15).  Inﬂuenza  vaccination  was  not associated  with  hospitalization  after  non-inﬂuenza
respiratory  illness  (aOR  = 1.14;  95%  CI:  0.84,  1.54).
Conclusions:  Inﬂuenza  vaccination  did  not  reduce  the  risk  of  subsequent  hospital  admission  among
patients  with  vaccine  failure.  These  ﬁndings  do not support  the  hypothesis  that vaccination  mitigates
inﬂuenza  illness  severity.. Introduction
Inﬂuenza is an important cause of death and serious illness,
articularly among adults aged ≥65 years and those with certain
nderlying chronic conditions. In the United States, approximately
26,000 hospital admissions are attributed to inﬂuenza each year
1]. As a result, annual inﬂuenza vaccination is recommended
or all persons aged ≥6 months to prevent seasonal inﬂuenza
nfection and its complications [2]. However, inﬂuenza vaccine
ailure is common even during seasons with optimal antigenic
atch between circulating and vaccine viruses. Among adults,
accine efﬁcacy in preventing laboratory conﬁrmed inﬂuenza ill-
ess is estimated to be approximately 60% [3]. Similar efﬁcacy has
een reported for preventing hospital admission with laboratory
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conﬁrmed pandemic or seasonal inﬂuenza [4–10]. It is not clear if
inﬂuenza vaccination prevents serious outcomes by primary pre-
vention of inﬂuenza infection, by reducing severity of inﬂuenza
illness, or both.
We  conducted a population based study of laboratory conﬁrmed
inﬂuenza among adults aged ≥20 years over multiple seasons to
determine if receipt of same-season inﬂuenza vaccine was associ-
ated with reduced risk of hospital admission within 14 days after
onset of inﬂuenza illness.
2. Methods
2.1. Study population and design
This was  a secondary analysis of data from population-based
studies of inﬂuenza vaccine effectiveness during eight inﬂuenza
seasons, 2004–05 through 2012–13, in Marshﬁeld, Wisconsin
[11–14]. In this community, residents receive nearly all outpatient
Open access under CC BY license.and inpatient care from the Marshﬁeld Clinic. A single acute care
hospital (St. Joseph’s) serves the study population, and both inpa-
tient and outpatient diagnoses are accessible through a combined
electronic medical record. The electronic medical record captures
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0% of outpatient visits, 95% of hospital discharges, and 99% of
eaths for the residents in the area [15–18].
During each inﬂuenza season, eligible community dwelling
esidents were recruited by trained research coordinators dur-
ng or after an inpatient or outpatient medical encounter for
cute respiratory illness. Research coordinators used an electronic
ppointment system to identify and recruit eligible persons in all
rimary care clinics and in urgent care on weekdays, evenings,
nd weekends. Eligible persons were also recruited at the hos-
ital that is contiguous with Marshﬁeld Clinic. Most ill persons
ho were not approached during a clinical encounter were iden-
iﬁed on the following day by use of electronic diagnosis codes
ntered by attending physicians (ICD-9-CM codes 382.0, 382.4,
82.9, 460–466, 480, 483–486, 487, 490, 780.6, and 786.2). These
ndividuals were contacted by telephone, and a swab sample was
btained at home from those who were eligible and consented.
Participants completed a short interview to assess illness symp-
oms and onset date; nasopharyngeal swabs were obtained for
nﬂuenza testing. Real-time reverse transcription polymerase chain
eaction (RT-PCR) and viral cultures were performed at the Marsh-
eld Clinic Research Foundation as previously described [11].
ulture alone was performed on samples collected in 2004–05
nd RT-PCR was performed in subsequent years. Subtype results
ased on RT-PCR were not available for 11% of inﬂuenza A positive
amples. For those samples, the subtype was assumed to be the pre-
ominant subtype identiﬁed among study participants during that
eason. This analysis excluded the 2009–10 season because mono-
alent vaccine was not available to the local population when the
andemic wave arrived in October–November 2009, and inﬂuenza
as absent from the study population in the subsequent winter
onths.
.2. Inﬂuenza vaccination status
Inﬂuenza vaccination status was determined by a real-time,
nternet-based vaccination registry used by all public and pri-
ate vaccination providers serving the population (http://www.
ecin.org). A validation study of the registry during the 2006–07
nd 2007–08 inﬂuenza seasons demonstrated that the registry cap-
ured 95% of all inﬂuenza vaccinations that were received by study
articipants [19]. A similar high level of capture was  demonstrated
n a validation study during the 2011–12 season (unpublished
ata). Adults were classiﬁed as vaccinated if they had received
nﬂuenza vaccine ≥14 days before the onset of illness.
.3. Ascertainment of hospital admissions and clinical history
Dates of hospital admission and discharge diagnoses were iden-
iﬁed from the electronic medical record for a 14 day period after
nset of inﬂuenza illness. To adjust for use of antiviral drugs, we
xtracted dates of antiviral prescriptions for all participants.
.4. Outcome and covariates
The main outcome was  an acute care hospital admission occur-
ing within 14 days of inﬂuenza symptom onset. Although most
ospital admissions occurred after an outpatient enrollment, some
articipants were initially enrolled and swabbed after admission
o the hospital. Covariates included age, gender, antiviral pre-
cription, speciﬁc high risk medical conditions, year, and inﬂuenza
ype/subtype [A/H3N2, A/H1N1, pandemic H1N1 (A/H1N1pdm09),
]. Study participants were classiﬁed as having a high risk med-
cal condition if they had at least one visit during a recent 12
onth period with an ICD-9 CM diagnosis code of interest. High
isk conditions were classiﬁed into the following groups: cancer,
ardiovascular disease, diabetes, pulmonary, and other. 32 (2014) 453– 457
Antiviral prescription was deﬁned as a prescription of
oseltamivir, zanamivir, amantadine, or rimantadine within 14
days of symptom onset for persons not hospitalized and between
symptom onset and hospital admission for persons who  were hos-
pitalized.
2.5. Analyses
We  restricted the analysis of hospital admissions to enrolled
adults aged ≥20 years because inﬂuenza-related hospitalization
was less common in children, and potential confounding factors
are likely to be different for adults and children.
Studies of inﬂuenza vaccination and hospital admission are
particularly susceptible to confounding, since persons who are vac-
cinated may  be more likely to have pre-existing chronic medical
conditions or other risk factors for hospital admission. To minimize
confounding by indication for vaccination, we used a propen-
sity score regression adjustment [20,21]. Propensity scores allow
adjustment for multiple potential confounders when the data are
too sparse to include a separate effect for each potential confounder
in the regression model. The propensity scores were generated
from a multivariable logistic regression model that assessed the
probability of inﬂuenza vaccination as a function of the poten-
tial confounders. In the propensity model, the dependent variable
was inﬂuenza vaccination status and the independent variables
were potential confounders identiﬁed a priori. The propensity score
covariates included age, gender, cancer, cardiovascular disease, dia-
betes, pulmonary disorders, other high risk conditions, and year.
The propensity scores from the model were then included as a con-
tinuous variable in the ﬁnal logistic regression model that assessed
the association between inﬂuenza vaccination and hospital admis-
sion.
To determine the effect of inﬂuenza vaccination among persons
with laboratory conﬁrmed inﬂuenza, the ﬁnal logistic regres-
sion model predicting hospital admission included the following
covariates: propensity score, inﬂuenza vaccination, age group,
inﬂuenza type/subtype, receipt of antiviral drug prescription. The
primary analysis included all study participants with laboratory
conﬁrmed inﬂuenza. Secondary analyses included subgroups based
on inﬂuenza type (A or B). We  excluded the small number of partici-
pants with both A and B infection because the risk of hospitalization
may  be different for those co infected with both types and persons
with unknown vaccination status.
Since the primary outcome included all hospital admissions dur-
ing a 14 day period, we performed a secondary analysis restricted
to hospital admissions that were directly related to inﬂuenza
infection. These included individuals who received any discharge
diagnosis (among the top three diagnosis codes) for inﬂuenza,
pneumonia, bronchitis, exacerbation of chronic pulmonary disease,
or acute respiratory infection. In addition, one individual with a
discharge diagnosis of fever was included in this group because
symptoms of inﬂuenza like illness were present at the time of
admission. We also performed an analysis restricted to persons who
were enrolled in the outpatient setting and subsequently admitted
to the hospital.
Finally, we evaluated residual confounding by examining the
association between inﬂuenza vaccination and hospital admission
among study participants with a negative inﬂuenza test in a logis-
tic regression model. The propensity scores for study participants
with a negative inﬂuenza test (i.e., non-inﬂuenza respiratory ill-
ness) were generated using the same method as described above. If
the propensity scores adequately adjusted for confounding, there
should be no association between inﬂuenza vaccine receipt and
hospital admission in that group. We  assumed that confounders
would be the same for inﬂuenza negative and inﬂuenza positive
study participants.
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Table 1
Clinical and demographic characteristics and inﬂuenza vaccination status for adult
study participants with laboratory conﬁrmed inﬂuenza.
Patient characteristics Vaccinated Unvaccinated p
n  = 552 n = 837
No. (%) No. (%)
Age <0.0001
20–49 years 208 (38) 584 (70)
50–59 years 108 (20) 161 (19)
60–69 years 102 (18) 57 (7)
70–79 years 88 (16) 24 (3)
≥80 years 46 (8) 11 (1)
Male 195 (35) 388 (46) <0.001
Received antiviral prescription 117 (21) 199 (24) 0.3
High risk conditions
Cancer 64 (12) 20 (2) <0.0001
Cardiovascular 130 (23) 79 (9) <0.0001
Diabetes 98 (18) 42 (5) <0.0001
Pulmonary disordersa 122 (22) 84 (10) <0.0001
Other high riskb 109 (20) 69 (8) <0.0001
Season <0.0001
2004–05 80 (14) 34 (4)
2005–06 16 (3) 14 (2)
2006–07 12 (2) 22 (3)
2007–08 161 (29) 339 (41)
2008–09 43 (8) 101 (12)
2010–11 41 (7) 73 (9)
2011–12 36 (7) 56 (7)
2012–13 163 (30) 198 (24)
a Pulmonary disorders included pulmonary tuberculosis, other respiratory tuber-
culosis, other diseases due to mycobacteria, sarcoidosis, cystic ﬁbrosis, alpha-1
anti-trypsin deﬁciency, chronic bronchitis, emphysema, asthma, bronchiectasis,
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Table 2
Characteristics associated with inﬂuenza vaccination among adults hospitalized
with conﬁrmed inﬂuenza.
Total
persons
Persons
vaccinated
Risk ratio
No. No. (%) (95% CI)
Age
20–49 years 21 6 (29) 1.0
50–59 years 10 6 (60) 2.10 (0.90, 4.89)
60–69 years 15 9 (60) 2.10 (0.95, 4.64)
70–79 years 14 11 (79) 2.75 (1.33, 5.70)
≥80 years 19 15 (79) 2.76 (1.35, 5.65)
Gender
Male 34 21 (62) 1.07 (0.74, 1.54)
Female 45 26 (58) 1.0
High risk conditions
Cancer
Yes 14 11 (79) 1.42 (1.00, 2.01)
No 65 36 (55) 1.0
Cardiovascular
Yes 29 22 (76) 1.52 (1.07, 2.14)
No 50 25 (50) 1.0
Diabetes
Yes 14 10 (71) 1.25 (0.85, 1.86)
No 65 37 (57) 1.0
Pulmonary disorders
Yes 29 19 (66) 1.17 (0.82, 1.68)
No 50 28 (56) 1.0
Other high riska
Yes 20 15 (75) 1.38 (0.98, 1.95)
No 59 32 (54) 1.0xtrinsic allergic alveolitis, chronic airway obstruction, and coal workers.
b Kidney disease, liver disease, blood disorders, immunosuppressive disorders,
etabolic disorders, and neurological/musculoskeletal disorders.
Unadjusted risk ratios were used to compare the risk of inﬂuenza
accination among adults hospitalized with inﬂuenza. All analy-
es were performed using SAS 9.3 (SAS Institute Inc., Cary, NC);
-values <0.05 were considered signiﬁcant.
. Results
During the 8 inﬂuenza seasons, 4996 adults with acute respira-
ory illness seeking medical care were enrolled. Inﬂuenza infection
as laboratory conﬁrmed for 1393 persons; 1020 (73%) had type
 infection, 369 (26%) had type B infection, and 4 (<1%) were posi-
ive for both type A and B. Most (84%) inﬂuenza A infections were
3N2 subtype, followed by H1N1 (10%) and H1N1pdm09 (6%). The
umber of inﬂuenza A positive study participants ranged from 18
n the 2005–06 season to 356 in the 2007–08 season. The num-
er of inﬂuenza B positive study participants ranged from 5 in the
006–07 season to 144 in the 2007–08 season.
Among persons with laboratory conﬁrmed inﬂuenza and known
accination status, 583 (42%) were males, 540 (39%) had at least
ne high risk condition, 316 (23%) were prescribed antiviral medi-
ations, and 31 (2%) were enrolled after admission to the hospital.
he proportion vaccinated differed with respect to age, gender, and
resence of high risk conditions (Table 1). In particular, inﬂuenza
accination was more common in older adults and women. The
edian age was 55 years [interquartile range (IQR): 41, 69] among
dults who were vaccinated and 41 years (IQR: 30, 52) among
dults who were not vaccinated (p < 0.001). Vaccination was also
ore common among persons with cancer, cardiovascular disease,
iabetes, pulmonary disorders, and other high risk conditions com-
ared to those without these high risk conditions. Similar patterns
ere observed when examined by inﬂuenza type.
Seventy-nine patients with laboratory conﬁrmed inﬂuenza
ere admitted to the hospital within 14 days of symptom onset: 62
6%) of 1020 with inﬂuenza A and 17 (5%) of 369 with inﬂuenza B.a Kidney disease, liver disease, blood disorders, immunosuppressive disorders,
metabolic disorders, and neurological/musculoskeletal disorders.
The median time from symptom onset to hospital admission was  3
days (IQR: 2–5 days). Seventy (89%) had discharge diagnoses codes
that were consistent with an acute respiratory illness or exacer-
bation of chronic pulmonary disease. Among hospitalized patients,
those who  were older were more likely to be vaccinated compared
to those aged 20–49 years and those with a cardiovascular high
risk condition were more likely to be vaccinated compared to those
without a cardiovascular high risk condition (Table 2). Vaccination
status among hospitalized patients was not associated with gender
or the other high risk conditions examined.
Among patients with laboratory conﬁrmed inﬂuenza, inﬂuenza
vaccination was  not associated with a decreased risk of hospital-
ization following onset overall or by inﬂuenza type (Table 3). The
propensity score adjusted odd ratio of hospitalization for vacci-
nated compared to unvaccinated patients was 1.08 (95% CI: 0.62,
1.88), 1.35 (95% CI: 0.71, 2.57), and 0.67 (95% CI: 0.21, 2.15) over-
all, for type A infection, and for type B infection, respectively. The
results were similar in secondary analyses where the outcome was
hospital admission for acute respiratory illness rather than all hos-
pital admissions and for analyses restricted to patients enrolled in
the outpatient setting and subsequently hospitalized (Table 3).
In the 3603 adults with non-inﬂuenza respiratory illness, there
was no association between inﬂuenza vaccination and hospital
admission within 14 days after illness onset (propensity score
adjusted OR = 1.14; 95% CI: 0.84, 1.54; p = 0.4).
4. Discussion
In this multi-season study, we examined the hypothesis that
vaccination may  mitigate inﬂuenza illness severity and reduce the
risk of hospital admission. We  found that vaccinated and unvac-
cinated individuals with inﬂuenza had a similar risk of hospital
admission after adjustment for propensity to be vaccinated, regard-
less of inﬂuenza type. This suggests that inﬂuenza vaccination
prevents serious outcomes by primary prevention of inﬂuenza
infection.
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Table 3
Propensity score adjusted association between inﬂuenza vaccination status and hospital admission within 14 days after illness onset for study participants with laboratory
conﬁrmed inﬂuenza. Propensity scores incorporated factors associated with receipt of inﬂuenza vaccine, including age, gender, cancer, cardiovascular disease, diabetes,
chronic  pulmonary disease, other high risk conditions, and year.
All hospital admissions within 14 days of illness onset Admissions for
acute
respiratory
illnessa
Admission
after outpatient
enrollmentb
No. cases (%
vaccinated)
Vaccinated No.
(%) hospitalized
Unvaccinated
No. (%)
hospitalized
Crude OR (95%
CI)
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any inﬂuenza
virus
1389 (40) 47 (9) 32 (4) 2.34 (1.47,
3.72)
1.08c (0.62,
1.88)
0.95c (0.52,
1.70)
1.11c (0.56,
2.21)
Inﬂuenza A
virus
1020 (43) 40 (9) 22 (4) 2.57 (1.50,
4.39)
1.35d (0.71,
2.57)
1.23d (0.62,
2.44)
1.21d(0.54,
2.71)
Inﬂuenza B
virus
369 (31) 7 (6) 10 (4) 1.58 (0.59,
4.27)
0.67 (0.21,
2.15)
0.54 (0.16,
1.81)
1.02 (0.28,
3.82)
a Nine patients with hospital admission that did not appear to be associated with inﬂuenza infection were excluded.
b Thirty one patients were enrolled after hospital admission and were excluded.
c Adjusted for propensity score, age, inﬂuenza type/subtype (A/H3N2, A/H1N1, A/H1N1pdm09, B), and receipt of antiviral drug prescription.
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nd  receipt of antiviral drug prescription.
In the past decade, multiple observational studies of vac-
ine effectiveness have been performed using medically attended
nﬂuenza (conﬁrmed by RT-PCR) as the primary endpoint. Most of
hese studies have assessed vaccine effectiveness for preventing
utpatient inﬂuenza illness, but few have focused on vaccine effec-
iveness for preventing hospitalization with laboratory conﬁrmed
nﬂuenza [4–10,22–25]. In these studies where the comparison
roups were those without inﬂuenza, vaccine effectiveness esti-
ates ranged from 25% to 74%. An important ﬁnding from these
tudies is that vaccination provides moderate beneﬁt against
nﬂuenza hospitalization, presumably due to primary prevention
f inﬂuenza illness.
To our knowledge, one other study has examined the associ-
tion between vaccination and hospital admission among persons
ith inﬂuenza. Despite a different study population and most cases
eing caused by A/H1N1pdm09, they had similar ﬁndings to our
tudy: vaccination did not reduce the risk of hospitalization [9].
dditionally, they found that hospitalized patients who  were vacci-
ated were less likely to have had severe disease. However, because
he study was observational, it is not possible to know whether this
ssociation was due to vaccination, residual confounding, or con-
ounding from unmeasured factors. Due to the limited number of
ospitalized cases in our study, we were unable to assess the impact
f vaccination on severity of cases among those hospitalized.
We attempted to minimize confounding with a propensity score
hat adjusted for the likelihood of inﬂuenza vaccination based
n multiple covariates. The propensity score model was  tested
n study participants with non-inﬂuenza respiratory illness, since
n association between vaccination and hospital admission is not
iologically plausible in the absence of inﬂuenza. The model with
ropensity score adjustment showed no evidence of confounding
n this group: the odds ratio for hospital admission in vaccinated
ersus unvaccinated adults with non-inﬂuenza illness was 1.1
p = 0.4). This supported the validity of the propensity score model
o examine the association between vaccination and hospitaliza-
ion among patients with inﬂuenza.
Strengths of this study included systematic recruitment and
ample collection from a community cohort with medically
ttended acute respiratory illness, use of a highly sensitive and spe-
iﬁc RT-PCR assay, access to a validated immunization registry, and
omplete capture of hospital admissions from the electronic med-
cal record. However, several limitations should be acknowledged.
irst, hospitalization due to inﬂuenza is rare in healthy adult popu-
ations. Despite eight seasons, there were few hospitalizations in09), and receipt of antiviral drug prescription. Adjusted for propensity score, age,
our study, all of which were from a single hospital in central Wis-
consin. Second, antigenic characterization was not performed for
many positive samples, and minor antigenic drift can be difﬁcult
to detect and interpret. As a result, we were not able to assess
the potential impact of antigenic variability. The 2007–08 season
accounted for the majority of A (H3N2) infections, and during that
year there was circulation of A/Brisbane/10/2007-like viruses that
were minor antigenic variants from the vaccine strain [26]. Third,
our classiﬁcation of high risk medical conditions was  based on
ICD-9 diagnosis codes without medical record validation. How-
ever, all diagnoses were entered by physicians and automatically
mapped to ICD-9 codes in the electronic medical record, which
reduced the potential for coding error. Finally, our study population
included primarily outpatient inﬂuenza cases and there may  have
been differential health care seeking behavior between vaccinated
and unvaccinated individuals. We  cannot exclude the possibility
that vaccinated individuals had milder inﬂuenza illness and did not
seek medical attention. In that scenario, vaccination would have
reduced illness severity, leading to fewer outpatient visits and hos-
pitalizations, but this would not be evident when comparing the
risk of hospitalization in vaccinated and unvaccinated outpatients.
However, we note that estimates of vaccine effectiveness in the out-
patient setting are generally similar to estimates of efﬁcacy based
on randomized clinical trials, and the primary endpoint for clini-
cal trials is inﬂuenza illness rather than severity. Because of these
limitations, results should be interpreted with caution.
Hospitalization is an important complication of inﬂuenza infec-
tion from a public health and an economic perspective. Available
evidence suggests that inﬂuenza vaccine provides moderate pro-
tection against inﬂuenza-related hospitalization. Further research
is warranted to assess the impact of vaccination in preventing
severe outcomes among vaccine failures, including differences by
type, subtype, and lineage.
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